[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vestibular-migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vestibular-migraine":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,78,110,138,169,195,225,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100641779","phase-4-comparing-migraine-preventive-therapies-vs-anti-cgrp-therapies-for-tinnitus-in-patients-with-migraine-compact-pm-100641779",false,"NCT07655440","Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)","Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)","COMPACT-PM","Inclusion Criteria:\n\n* Age 18 years or older\n* Non-pulsatile, subjective tinnitus present for at least 6 months\n* Tinnitus Functional Index (TFI) score greater than 25 at screening, indicating at least mild-to-moderate tinnitus burden\n* Current or past history of migraine, vestibular migraine, or episodic headache disorder, diagnosed by a physician or meeting ICHD-3 criteria\n* Clinically appropriate candidate for migraine preventive therapy as determined by the treating clinician\n* Stable medication regimen for at least 3 months prior to enrollment (no new medications started or stopped within 3 months of screening)\n* Ability to provide written informed consent\n* Ability to complete self-report questionnaires in English or with certified interpreter assistance\n* Willingness to attend three in-person study visits over 24 weeks and complete daily symptom diaries\n\nExclusion Criteria:\n\n* Pulsatile tinnitus or objective tinnitus (tinnitus audible to examiner)\n* Pregnancy, planned pregnancy during the study period, or breastfeeding\n* Participation in any other interventional tinnitus treatment research protocol during the study period\n* Currently receiving a CGRP-targeting medication (for participants being considered for the conventional arm) or a conventional migraine preventive medication listed in this protocol (for participants being considered for the CGRP arm) - to avoid within-arm ineligibility at randomization\n* Known contraindication to all medications within the assigned study arm\n* History of serious cardiovascular event (myocardial infarction, stroke, or unstable angina) within 6 months of enrollment\n* Severe hepatic or renal impairment that would contraindicate study medications\n* Active psychiatric disorder requiring medication adjustment within 3 months of enrollment\n* Known hypersensitivity or prior serious adverse reaction to a medication within the assigned study arm\n* Active malignancy or life expectancy less than 12 months\n* Inability to complete study procedures or follow-up visits in the judgment of the investigator","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head \\& Neck Surgery at Stanford University.",[27,28,29,30],"Migraine Associated Vertigo","Tinnitus","Migraine","Vestibular Migraine",[32,33,34,35,36],"tinnitus","migraine","vestibular migraine","migraine-associated tinnitus","CGRP","NOT_YET_RECRUITING","2026-06-15",{"date":40,"type":41},"2026-06-17","ACTUAL",{"date":43,"type":21},"2026-07",{"date":45,"type":21},"2031-07",{"name":47,"class":48},"Stanford University","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100633855","validation-of-the-vestibular-migraine-patient-assessment-tool-and-handicap-inventory-vm-pathi-for-adolescents-100633855","NCT07532109","Validation of the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI) for Adolescents","Experimental Patient Inclusion Criteria:\n\n* Patients aged 10-20 years old.\n* Patients meeting the 2021 Bárány Society criteria for definite vestibular migraine of childhood (dVMC) or probable vestibular migraine of childhood (pVMC).\n\nExperimental Patient Exclusion Criteria:\n\n* Patients who do not meet the 2021 Bárány Society criteria for definite vestibular migraine of childhood (dVMC) or probable vestibular migraine of childhood (pVMC).\n* Non-English language preference patients.\n\nControl Patient Inclusion Criteria:\n\n* Patients aged 10-20 years old.\n* Patients who do not have a history of dizziness and\u002For migraines.\n\nControl Patient Exclusion Criteria:\n\n* Patients who have a history of dizziness and\u002For migraines.\n* Non-English language preference patients.",true,"10 Years","20 Years",{"count":59,"type":21},70,"OBSERVATIONAL","Vestibular migraine (VM) is the most common cause of episodic dizziness in children and adults. Dizziness, especially in conjunction with other migraine symptoms (headache, photophobia, phonophobia, etc.) can profoundly decrease quality of life, so effective treatment of VM is of utmost importance.\n\nUnfortunately, there is sparse research on effective treatment methods for VM, and even less for vestibular migraine of childhood (VMC), for which diagnostic criteria was recently defined by the Bárány Society in 2021. Lifestyle changes are often a large part of the treatment plan, and pharmacological treatment is also common, but their efficacies in treating VMC are less than ideal. In truth, there is yet to be a \"gold-standard\" medication or other treatment method for VMC.\n\nThere is a dire need for structured research on the efficacy of different treatments, both lifestyle and pharmacological, in treating pediatric patients with vestibular migraine. However, in order to conduct this research, a validated inventory to objectively and reliably measure vestibular migraine symptoms in children is required. Existing validated measures often used to assess vestibular migraine in children, do not account for the wide array of other symptoms associated with pediatric vestibular migraine.\n\nThe Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI) - pronounced \"Vempathy\" - is a symptom inventory designed by Dr. Jeffrey Sharon and colleagues specifically to assess VM in adults. His group also worked to estimate a minimal clinically important difference (MCID) for the VM-PATHI in adults, finding that a change in VM-PATHI score of 6 points or more likely demonstrates an authentic clinical change in patient condition.\n\nThis study aims to validate the VM-PATHI for adolescents with VM and estimate a MCID for the VM-PATHI in adolescent patients with vestibular migraine.",[30],[34,64,65,66,67,68],"pediatric dizziness","pediatric migraine","questionnaire","inventory","VM-PATHI","2026-04-09",{"date":71,"type":41},"2026-04-15",{"date":43,"type":21},{"date":74,"type":21},"2027-06",{"name":76,"class":48},"Boston Children's Hospital",3,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":60,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100632775","genetic-and-biohumoral-factors-involved-in-menires-disease-and-their-correlation-with-phenotypes-100632775","NCT07518069","Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes","Genetics and Biohumoral Factors in Menière's Disease","Menière09","Inclusion Criteria:\n\n* Patients with definite Menière's Disease according to the criteria of the Barany Society\n\nExclusion Criteria:\n\n* surgically treated before the examination or if they had undergone intratympanic therapy with steroids or gentamicin",{"count":87,"type":21},250,"6 Months","Aim of this work was to assess the role of polymorphisms belonging to genes involved in the regulation of ionic homeostasis in Caucasian patients with Ménière Disease (MD) and compare results with a cohort of patients affected by vestibular migraine and a cohort of non vestibular subjects",[91,92,30],"Vertigo","Meniere's Disease",[94,95,96,97,98],"episodic vertigo","Menière's Disease","Vestibular migraine","genetics","biohumoral markers","RECRUITING","2026-04-01",{"date":102,"type":41},"2026-04-08",{"date":104,"type":41},"2025-04-09",{"date":106,"type":21},"2027-04-12",{"name":108,"class":48},"IRCCS San Raffaele",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":109},"100621747","early-phase-1-virtual-reality-and-biofeedback-for-adolescents-with-chronic-dizziness-100621747","NCT07374640","Virtual Reality and Biofeedback for Adolescents With Chronic Dizziness","Inclusion Criteria:\n\n\\- Patients who previously or are currently seen in our program who have not already undergone BFB, CBT, and SDERP for treatment of their chronic dizziness.\n\nExclusion Criteria:\n\n* Patients without chronic dizziness.\n* Patients for whom written consent is not available.\n* Patients who exhibit psychotic features, have untreated mental health conditions, or have an intellectual disability, developmental delay, or decisional impairment.\n* Non-English language preference patients.\n* Patients with a history of seizures, at risk of seizures, or who have a diagnosis of epilepsy.","13 Years","25 Years",{"count":119,"type":21},12,[121],"EARLY_PHASE1","Both persistent postural-perceptual dizziness (PPPD) and vestibular migraine (VM) are common diagnoses in patients presenting to physicians for evaluation of vestibular symptoms such as dizziness and vertigo. Although they are most often described in the adult population, they are also common in children and adolescents with dizziness. Chronic dizziness profoundly affects quality of life, often keeping children out of school and inhibiting their participation in the normal activities of childhood and adolescence. Overall, chronic dizziness is suspected to be due in large part to a \"rewiring\" of the brain that alters how cues related to balance and orientation are processed, with overreliance on visual inputs to maintain balance and equilibrium being a common development. Thus, chronic dizziness, especially that which is due to PPPD, is often caused by visual triggers.\n\nA multi-modal approach is often taken to treat chronic dizziness, attempting to recalibrate this maladaptive \"rewiring\" and return the sensory system to normal function. Given the role that visual inputs play in developing and perpetuating chronic dizziness, habituation to visual stimuli should be a significant component to treatment. Treatments often include cognitive behavioral therapy (CBT), systematic desensitization exposure response prevention (SDERP), and biofeedback therapy (BFB). However, these visually provoked symptoms are often resistant to treatment. One reason for this may be that visual stimuli are difficult to replicate in the clinic or office. One way to address this gap in treatment is through virtual reality (VR) technology, which immerses patients in realistic visual environments.\n\nVR has not been explicitly described in the treatment of PPPD or chronic dizziness, but it has been piloted, and shown to be effective, in the rehabilitation of peripheral vestibular dysfunction. This study aims to integrate VR into the current PPPD\u002Fchronic dizziness techniques of CBT, SDERP, and BFB. The investigators will use a commercially available VR headset, which enables the use of VR in the office setting in a relatively low-cost form of VR technology. This study will evaluate the feasibility and effectiveness of VR in conjunction with CBT, SDERP, and BFB to investigate if VR technology enhances previously established effective treatments to reduce chronic dizziness and PPPD.",[124,30,125],"Persistent Postural Perceptual Dizziness","Chronic Dizziness",[127,30,125,128,129],"Persistent Postural-Perceptual Dizziness","Virtual Reality","Biofeedback","2026-03-05",{"date":132,"type":41},"2026-03-06",{"date":134,"type":21},"2026-03",{"date":136,"type":21},"2027-05",{"name":76,"class":48},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":109},"100621247","exploring-mild-electrical-vestibular-stimulation-as-a-new-treatment-for-dizziness-and-migraine-symptoms-100621247","NCT07368140","Exploring Mild Electrical Vestibular Stimulation as a New Treatment for Dizziness and Migraine Symptoms","Electrical Vestibular Stimulation as a Novel Neuromodulation Therapy for Vestibular Migraine: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical diagnosis of VM, according to the ICHD-3 and Barany Society criteria.\n* Experienced at least one vestibular migraine episode in the previous month.\n* Ability to provide informed consent and comply with study requirements.\n* Willingness to attend six EVS sessions over a two-week period and complete all required testing and diaries.\n* Physical ability to stand unassisted for at least one minute and walk 25 feet without assistance.\n\nExclusion Criteria:\n\n* Diagnosis of other vestibular disorders (e.g. benign paroxysmal positional vertigo, Meniere's disease, vestibular neuritis) that may confound results.\n* History of seizure disorder, epilepsy, or unexplained loss of consciousness.\n* Presence of implanted electronic medical devices, such as pacemakers or cochlear implants.\n* Pregnancy or plans to become pregnant during study period.\n* Use of vestibular suppressant or migraine prophylactic medications that cannot be paused or maintained at a stable dose during the two-week EVS intervention period. Acute use of rescue medications during a severe attack is permitted, however, participants who initiate new medication or undergo dose changes during the intervention window will be excluded from final analysis.\n* Current medical, psychiatric, or neurological condition (other than VM) that could interfere with participation.\n* Cognitive or language impairments that preclude understanding of instructions or valid completion of outcome measures.",{"count":146,"type":21},50,[148],"NA","Vestibular migraine is a common cause of repeated dizziness, imbalance, and headaches that affects about three percent of Canadians. Many people do not find relief from current medications, leaving them with long term problems in balance and daily function. This study will test a new, non drug based treatment called electrical vestibular stimulation (EVS). EVS delivers gentle, safe electrical signals behind the ears to activate the brain's vestibular pathways.\n\nFifty adults with vestibular migraine will take part. Half will receive real stimulation, and half will receive a sham (placebo) treatment. Each participant will attend six sessions over two weeks. Around the treatment period, they will record dizziness and migraine symptoms in a daily diary and complete questionnaires and balance tests using motion sensors.\n\nThe main goal is to determine whether EVS can be delivered safely and comfortably in adults with vestibular migraine and whether participants can complete the sessions and assessments as planned. Results will also show whether symptoms or balance improve, providing essential information to design a larger clinical trial and, ultimately, develop new, accessible treatments for dizziness and migraine.",[30],[152,153,30,91,154,155,156,157,158,159],"Electrical Vestibular Stimulation","Galvanic Vestibular Stimulation","Dizziness","Balance and gait","Inertial Measurement Units","Motion sensitivity","Posturography","Neuromodulation","2026-01-20",{"date":162,"type":41},"2026-01-26",{"date":164,"type":21},"2026-02-01",{"date":166,"type":21},"2029-12-31",{"name":168,"class":48},"University of Calgary",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":179,"studyType":60,"phases":4,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100608568","chinese-real-world-study-of-treatment-of-vestibular-migraine-100608568","NCT07203248","Chinese Real-world Study of Treatment of Vestibular Migraine","A Real-world Study on the Use of CGRP-targeted Medications for the Treatment of Vestibular Migraine in Chinese Patients","Inclusion Criteria:\n\n1. Male or female, aged between 18 and 75 years.\n2. Meet the following criteria established by the Barany Society for the diagnosis of vestibular migraine or probable vestibular migraine:\n\n   Vestibular Migraine A: At least five episodes with moderate or severe vestibular symptoms lasting from 5 minutes to 72 hours.\n\n   B: Current or past history of migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-3).\n\n   C: One or more migraine features during at least 50% of vestibular episodes:\n\n   Headache with at least two of the following characteristics: unilateral, pulsating, moderate or severe pain, worsening with routine physical activity.\n\n   Photophobia and phonophobia. Visual aura. D: Not better accounted for by another vestibular or ICHD diagnosis. Probable Vestibular Migraine A. At least five episodes with moderate or severe vestibular symptoms lasting from 5 minutes to 72 hours.\n\n   B. Meets only one of the criteria B or C for vestibular migraine (history of migraine or migraine features during episodes).\n\n   C. Not better accounted for by another vestibular or ICHD diagnosis.\n3. More than or equal to 4 days per month with confirmed vestibular symptom in the three months prior to enrollment (only required for group B).\n4. Able to complete at least 80% of the electronic diary during the treatment period.\n5. The investigator believes that the participant is able to read, understand, and complete the study questionnaires and headache diary.\n\nUnderstanding and compliance with the study procedures and methods, voluntary participation in this trial, and written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant women, breastfeeding women, or those unwilling to use approved contraceptive methods during study participation.\n2. Presence of a condition or abnormality that the investigator believes would affect the safety of the patient or the quality of the data.\n3. History of ear surgery (excluding ear tube surgery).\n4. Other vestibular diagnoses (excluding treated benign paroxysmal positional vertigo, BPPV). This includes Ménière's disease, superior semicircular canal dehiscence syndrome, vestibular neuritis, persistent postural-perceptual dizziness, unilateral or bilateral vestibular hypofunction, cerebellar or brainstem disorders, multiple sclerosis, or seasickness.\n5. More than two preventive migraine medications have failed.\n6. Previous or current treatment with CGRP class drugs.\n7. History of serious medical or psychiatric conditions, as judged by the treating physician (including significant coronary artery disease, peripheral vascular disease, cerebrovascular disease, renal disease, liver disease, Raynaud's disease, uncontrolled psychiatric illness, or past psychiatric hospitalization).\n8. History of mania, psychosis, or suicidal ideation.\n9. Acceptable if using no more than two migraine preventive medications (prescribed specifically for this purpose), with stable dosing for at least 2 months prior to study start.\n10. History of drug or alcohol abuse within the 12 months prior to screening, based on the participant's medical records or self-report.\n11. Those who have received or plan to receive botulinum toxin (e.g., Dysport®, Botox®, Xeomin®, Myobloc®, Jeuveau™) for therapeutic or cosmetic purposes in the head, face, or neck within 4 months prior to screening or during the study period.","75 Years",{"count":178,"type":21},2000,"12 Weeks","Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment. Acute treatment aims to reduce the severity and duration of a single episode, while preventive treatment aims to decrease the frequency, severity, and duration of attacks. Current acute treatments are primarily divided into pain relief and anti-dizziness, with specific drugs such as triptans and ergots being applicable for pain relief, but only betahistine has weak evidence for anti-dizziness, and relevant clinical evidence is very scarce. Preventive treatment mainly refers to migraine preventive treatments, with recommended medications including traditional drugs like topiramate, flunarizine, propranolol, etc., but the efficacy and safety of these drugs are limited. CGRP-targeted drugs are believed to play a role in the preventive treatment of VM, and there are related literature reports, but most are small-sample studies or retrospective studies. This study aims to explore the real-world efficacy of CGRP-targeted drugs in the acute and preventive treatment of VM through a prospective real-world study.",[30,154,91],[30,36,183,184,185],"acute treatment","preventive treatment","real-world","2025-09-24",{"date":188,"type":41},"2025-10-02",{"date":190,"type":21},"2025-12",{"date":192,"type":21},"2028-12",{"name":194,"class":48},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":55,"sex":17,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":206,"studyType":60,"phases":4,"briefSummary":207,"conditions":208,"keywords":215,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":109},"100434650","china-headache-and-vertigo-registry-study-100434650","NCT04939922","China Headache and Vertigo Registry Study","CHRS","Inclusion Criteria:\n\n* Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.\n* Male or female participants ages 4 to 99 years.\n* Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches.\n* Patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).\n\nExclusion Criteria:\n\n* Patients who were unable to complete scales such as headache diary.\n* Patients denied or unable to be admitted for long-term follow-up.","4 Years","99 Years",{"count":205,"type":21},10000,"30 Years","In the Chinese Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.",[209,210,29,211,212,213,30,214],"Headache Disorders, Primary","Headache Disorders, Secondary","Tension-Type Headache","Cluster Headache","Vertigo, Constant","Fibromyalgia",[29,216,91,30,214],"Headache Disorders","2025-07-22",{"date":219,"type":41},"2025-07-25",{"date":221,"type":41},"2017-06-12",{"date":223,"type":21},"2050-12-12",{"name":194,"class":48},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":55,"sex":17,"minAge":202,"maxAge":203,"enrollmentInfo":233,"targetDuration":235,"studyType":60,"phases":4,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":109},"100471387","international-headache-registry-study-100471387","NCT05418218","International Headache Registry Study","International Headache and Vertigo Registration Study","IHRS","Inclusion Criteria:\n\nThe following are requirements for entry into the study:\n\n1. Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.\n2. Male or female participants ages 4 to 99 years, inclusive, at Visit 1.\n3. Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches, and patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).\n\nExclusion Criteria:\n\n1. Patients who were unable to complete scales such as headache diary.\n2. Patients denied or unable to be admitted for long-term follow-up.",{"count":234,"type":21},200000,"60 Years","In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.",[209,210,29,211,91,30,214],[29,216,91,30,214],"2025-05-19",{"date":241,"type":41},"2025-05-23",{"date":243,"type":41},"2021-07-12",{"date":245,"type":21},"2082-12-31",{"name":194,"class":48},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100573621","phase-2-a-clinical-trial-of-rimegepant-for-vestibular-migraine-evaluation-pre-experiment-100573621","NCT06748664","A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment","Inclusion Criteria:\n\n* Male or female aged 18 to 75 years\n* Documentation of a VM diagnosis according to the Barany Society\u002F ICHD-31\n* More than 4 definite dizzy days per month in the 3 months prior to screen\n\n  ≥1 prior preventive treatment failure\n* E-diary compliance ≥ 80% during observational phase\n\nExclusion Criteria:\n\n* Pregnant women, lactating women, or reluctance to use approved contraception during study participation;\n* There is a condition or abnormality that the investigator believes will affect the safety of the patients or the quality of the data;\n* Allergic to the ingredients of Remeipine sulfate or sulfate;\n* Previous treatment with remejepam;\n* History of ear surgery (except for ear tube surgery);\n* Other vestibular diagnoses (excluding treated benign paroxysmal positional vertigo BPPV). Including Meniere's disease, superior semicircular canal prolapse syndrome, vestibular neuritis, persistent postural perceptual vertigo, unilateral or bilateral loss of vestibular function, cerebellar or brainstem disease, multiple sclerosis or sea sickness;\n* Failure of more than 2 preventive migraine drugs;\n* Previous or current treatment with CGRP drugs;\n* History of serious medical or mental illness (including significant coronary artery disease, peripheral vascular disease, cerebrovascular disease, kidney disease, liver disease, Raynaud's disease, uncontrollable mental illness, or past psychiatric hospitalization, at the discretion of the treating physician);\n* A history of mania, psychosis, or suicidal ideation;\n* Acceptable if no more than two drugs for migraine prevention (prescribed specifically for this purpose) are used and the dose has stabilized for 2 months before the start of the study;\n* History of drug or alcohol abuse based on the subject's medical record or self-reported report within 12 months before the screening period;\n* Bototoxin (e. g., Dysport®, ®, Xeomin®, Myobloc®, and JeuveauTM) for the head, face, or neck during the study.",{"count":254,"type":21},240,[256],"PHASE2","Vestibular migraine (VM) is one of the most common vestibular disorders, affecting 1.0% to 2.7% of the general population1, 7% of patients with definite migranous vertigo in dizziness clinics2, as well as 10.3% of VM patients in headache clinics3; 65% to 85% of VM patients are female1. Despite the relative prevalence of vestibular migraine, evidence-based medicine remains scarce. Two Cochrane reviews published in 2023 found that there is almost no evidence to support the use of medications for the acute treatment or preventive treatment of VM4,5.\n\nCalcitonin gene-related peptide (CGRP) has been established as an excellent target for the treatment of migraine. Animal studies suggest a link between CGRP and vestibular disorders. A prospective observational cohort study found that monoclonal antibodies targeting CGRP receptors and ligands were very effective for vestibular migraine (VM), with 90% of participants experiencing at least a 50% reduction in vertigo attacks6. A small-scale prospective randomized controlled trial showed that a monoclonal antibody targeting a CGRP ligand significantly reduced the number of dizziness days per month in VM patients compared to placebo7. The efficacy of CGRP small molecule antagonists for the preventive and acute treatment of migraines has been widely recognized8,9. Therefore, we speculate that Rimegepant is effective for the preventive and acute treatment of vestibular migraine.\n\nBy focusing on a large sample RCT, our study can offer new evidence-based treatment options for patients with vestibular migraine. This is crucial, as many patients with vestibular migraine may not respond well to conventional migraine treatments. Our findings could guide clinicians in choosing more effective therapeutic strategies.\n\nSpecifically in acute treatment of vestibular migraine, triptans have failed to show superiority when compared to placebo in treatment vestibular migraine symptoms10. Prochlorperazine, a vestibular sedative, is widely used for acute treatment of vestibular migraine but is known to chronify symptoms11. Should rimegepant demonstrate superiority to placebo in this study, rimegepant could potentially become the first-line treatment for vestibular migraine across the world.",[30,259],"Adults 18 Years and Older (no Other Exclusion Criteria)","2025-05-09",{"date":262,"type":41},"2025-05-14",{"date":264,"type":21},"2025-06-01",{"date":266,"type":21},"2027-05-01",{"name":194,"class":48}]